🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Basel, Switzerland
NCT07581496 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

T1G3 bladder cancer is a heterogeneous disease with a high risk of disease persistence after the first TUR-B, understaging, disease progression, bladder removal, and mortality. Current risk stratification is insufficient and needs improvement. Ct-DNA could identify patients with disease persistence, progression and could monitor and tailor therapy. It might improve patient risk stratification, avoiding under- and overtreatment, reducing morbidity and mortality. Primary objective is to investigate the detectability of ct-DNA in T1G3 urothelial bladder cancer patients and build a biobank through collection of different sample types (urine, plasma) in T1G3 bladder cancer patients which allows future retrospective testing.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * patients \> 18 years of age, able to give informed consent as documented by signature, * patients with a cystoscopically proven bladder cancer, suspicious for T1 stage, who will undergo TUR-B Exclusion Criteria: * Patients with metastases or concomitant upper tract tumor at diagnosis will * Patients with non T1 G3 cancers * Patients with upstaging, either at re-TUR-B or after immediate radical cystectomy * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. * Vulnerable persons (e.g. \< 18y of age, unable to consent to the study)
💊

What it tests

  • Not listed
📍

Where

2 sites
Universitätsspital Basel
Basel, Switzerland
Luzerner Kantonsspital
Lucerne, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy